AmplifiDx
AmplifiDx is dedicated to providing affordable, rapid, and accurate point-of-care molecular diagnostics, especially for family and women's health. Their innovative DX 100™ Platform supports healthcare professionals and patients with fast, reliable results, aiming to improve health outcomes worldwide. The company focuses on developing advanced multiplex technology for infectious diseases, including COVID-19, influenza, RSV, and sexually transmitted infections, with a mission to enhance global health through accessible diagnostics.
Industries
Nr. of Employees
small (1-50)
AmplifiDx
Agility Labs, 39655 Eureka Drive, Newark, CA 94560
Products
Compact point-of-care molecular diagnostic platform (under development)
A compact diagnostic instrument and consumable test system designed for point-of-care use that performs multiplex nucleic acid amplification testing from a single swab with sample-to-answer operation, delivering results during the patient visit.
Compact point-of-care molecular diagnostic platform (under development)
A compact diagnostic instrument and consumable test system designed for point-of-care use that performs multiplex nucleic acid amplification testing from a single swab with sample-to-answer operation, delivering results during the patient visit.
Services
Development of multiplex molecular diagnostic assays for decentralized clinical use under programmatic/contract funding.
Execution of clinical studies to generate performance metrics versus laboratory PCR standards for platform assays.
Development of multiplex molecular diagnostic assays for decentralized clinical use under programmatic/contract funding.
Execution of clinical studies to generate performance metrics versus laboratory PCR standards for platform assays.
Expertise Areas
- Point-of-care molecular diagnostics
- Multiplex NAAT assay development
- Clinical performance evaluation and validation
- Respiratory and sexual health diagnostic development
Key Technologies
- Nucleic acid amplification tests (NAAT)
- Multiplex molecular diagnostics
- Isothermal amplification (LAMP) (inferred)
- Sample-to-answer automation
News & Updates
AmplifiDx received additional funding from NIH's RADx® Tech program to accelerate the development of their diagnostic system, supporting the final stages of the DX 100 Platform and RespiFast™ Test for respiratory pathogens.
Coverage of AmplifiDx's funding from NIH to develop rapid COVID-19 testing solutions using their DX 100™ Platform.
Announcement of funding from NIH's RADx® Tech program to develop a compact, affordable molecular POC device for infectious diseases, including COVID-19, Flu A and B, and RSV.
AmplifiDx received additional funding from NIH's RADx® Tech program to accelerate the development of their diagnostic system, supporting the final stages of the DX 100 Platform and RespiFast™ Test for respiratory pathogens.
Coverage of AmplifiDx's funding from NIH to develop rapid COVID-19 testing solutions using their DX 100™ Platform.
Announcement of funding from NIH's RADx® Tech program to develop a compact, affordable molecular POC device for infectious diseases, including COVID-19, Flu A and B, and RSV.